It is known to be involved in the NGF pathway (Estrach et al, 2002), and activates RhoA with its GEF2 domain (Debant et al, 1996; Bateman and Van Vactor, 2001). and expressed TrkA and p75NTR on RTCPCR and Western blot. The motility of HSA/c, one of the OESCC cell lines overexpressing NGF, was significantly decreased by either neutralising anti-NGF antibody, an inhibitor of TrkA, or NGF-small interfering RNA in transwell migration assay. Our findings suggest that NGF is of potential interest not only as a prognostic factor, but also as a novel therapeutic target in OESCC. Keywords: NGF, TrkA, p75NTR, oesophageal cancer, immunohistochemistry, autocrine Oesophageal squamous cell carcinoma (OESCC) is one of the most lethal malignancies in the world including Japan, with a 5-year survival rate of 20C30% after curative surgery (Isono (2003) reported that NGF is involved in an autocrine loop in breast cancer. In oesophageal cancer, however, only one small clinical study on NGF expression has been reported (Zhu DNA polymerase (Invitrogen Corporation) were used in a total volume of 20?0?(2001a) showed that patients with NGF+ and p75NTR? had poorer survival in breast cancer. Further study is needed to clarify whether NGF shifts its receptor to TrkA from p75NTR. Next, we examined the role of NGF expression in OESCC cell lines. All five OESCC cell lines studied expressed NGF, TrkA, and p75NTR mRNA as well as protein. All of these OESCC cell lines showed TrkA phosphorylation on Western blot. Moreover, detectable levels of NGF were found in the conditioned media of the OESCC cell lines. The cellular motility was inhibited by NGF neutralising antibody, K252a (a TrkA inhibitor), and NGF-siRNA. The ability to inhibit cell motility was less with neutralising anti-NGF antibody than with K252a or NGF-siRNA, probably because it is difficult to neutralise NGF completely even with a specific antibody. Our results confirmed that the OESCC cell lines secrete biologically active NGF, which acts on TrkA in an autocrine manner to promote OESCC cell migration. These are compatible with our clinical findings from more than 100 cases of immunohistochemistry that overexpression of NGF is associated with lymph node metastasis and associated with poorer clinical outcome. To our knowledge, this is the first time to demonstrate NGF autocrine secretion in gastrointestinal cancer, although several previous studies have shown NGF autocrine secretion in other types of cancer (Weeraratna et al, 2000; Zhu et al, 2001, 2002; Paradol Paradol Dolle et al, 2003), as well as in noncancerous tissues (Torcia et al, 1996; Pincelli and Marconi, 2000). One candidate molecule that promotes cell movement in the NGF pathway is Rho-guanine nucleotide exchange factor (Rho-GEF) Trio. It is known to be involved in the NGF pathway (Estrach et al, 2002), and activates RhoA with its GEF2 domain (Debant et al, 1996; Bateman and Van Vactor, 2001). Further investigation is necessary to unveil the Paradol involvement of Rho-GEF Trio in NGF pathway of OESCC cells. Given the recent success of trastuzumab (Herceptin), imatinib mesylate (Gleevec), and gefitinib (Iressa) as chemotherapeutic agents, tyrosine kinase is definitely a promising target of molecular targeted medicine (Ross et al, 2004) for cancer therapy. Nerve growth factorCTrkA interactions could Rabbit polyclonal to OSGEP thus be a new therapeutic target. Nerve growth factor-siRNA might be one good option for OESCC treatment once tumour-specific siRNA delivering systems become available. In summary, results of our immunohistochemical study of 109 OESCC patients clearly suggest that NGF is an unfavourable prognostic factor in OESCC. Furthermore, NGFCTrkA interaction promotes cellular motility in an autocrine manner, which in turn contributes to poor prognosis of NGF-secreting OESCC. However, it has also been shown that chemical agents that block NGFCTrkA interaction can inhibit cellular motility, leaving the possibility that these agents might be able to improve clinical prognosis of NGF-producing OESCC. These findings suggest that NGF is of potential interest not only as a prognostic factor, but also as a novel therapeutic target in OESCC. Acknowledgments We thank Sakiko Shimada for culturing and providing the OESCC cell lines, and Dr Tsukasa Baba for his support for confocal microscopy. We also thank Takako Murai, Kumi Kodama, Akane Iwase, and Fumie Uemura for their technical assistance, and Dr Kan Kondo for his support in proofreading the manuscript. This work was supported in part by a Grant-in-aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant 17390363)..